Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while Vanguard Total World Stock Index Fund ETF trades at $160.39. The key difference: Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | VT | |
|---|---|---|
Market Cap | $1.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $6.79 | $162.39 |
52-Week Low | $2.84 | $134.19 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
VT trades at $160.92, down 0.5% on the day, with technical indicators showing a bullish moving average trend but neutral oscillators. The ETF maintains strong global diversification across 10,000+ stocks with a low 0.06% expense ratio. Recent institutional activity shows mixed positioning with some firms increasing stakes while others reduced holdings.
The outlook remains favorable for long-term investors seeking global equity exposure, though near-term volatility may persist due to trade policy uncertainty and midterm election seasonality. Key risks include geopolitical tensions and currency fluctuations affecting international holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
